

Schwarz Earns AO Foundation's Top Research Award

Edward Schwarz, PhD, Director of the Center for Musculoskeletal Research, has been awarded the 2024 Berton Rahn Research Award from the AO Foundation, an international consortium of surgeons and researchers focused on advancing care of musculoskeletal disorders through research, development, and provider education.

Schwarz, who is also the Richard and Margaret Burton Distinguished Professor of Orthopaedics, received the lifetime achievement award for his significant contributions to musculoskeletal research. He has published more than 380 journal articles and has served as Principal Investigator on NIH R01, R21, R43, P01, P30 and P50 grants. He received research funding from the Arthritis Foundation and National Multiple Sclerosis Society during his postdoctoral fellowship and has been funded by the NIH annually since 1999. Under his leadership, CMSR has remained in the top 10 NIH-funded musculoskeletal research institutions for more than a decade.

Schwarz served as Co-PI on the AO Trauma Clinical Priority Program – Bone Infection from 2012-2022. He has contributed to leading musculoskeletal research publications: he has served as Associate Editor of Arthritis Research & Therapy, Arthritis & Rheumatism, Journal of Bone & Joint Infection, and the Journal of Orthopaedic Research (JOR), and began his five-year term as Editor-in-Chief of JOR in March.

The Schwarz Lab focuses on inflammatory bone loss, such as that seen in rheumatoid arthritis, infections, tumor metastasis and wear debris-induced osteolysis around loose prosthetic implants. Schwarz is a leader in orthopaedic biologic therapy, for which his lab has developed a novel passive immunization for MRSA and bone targeted antibiotics. His lab is also interested in developing translational in vivo imaging outcome measures include near infrared imaging of lymphatic flow to detect arthritic flare, cone beam CT to assess bone healing in patients with orthopaedic implants, and intravital microscopy of bone infections.

Schwarz, who has been an Orthopaedic Research Society (ORS) member since 1999, has received many awards for his research achievements, including the ORS's Harris Award in 2003, the ORS/AAOS Kappa Delta Award in 2005, and the CORR/ORS Richard Brand Award for outstanding Orthopaedic Research in 2015. He also has served in many leadership and mentorship roles: he was a member of the ORS Board of Directors from 2006-2008, 2010-2011, and 2017-2019. He served the Orthopaedic Research and Education Foundation Study Section as a reviewer and Co-Chair from 2001-2007. He also served on many NIH Study Sections including Regular Membership and Co-Chair on Arthritis, Connective Tissue and Skin from 2012-2016 and Musculoskeletal Tissue Engineering from 2017-2023.

He has also served on the ORS Publications Committee as a member and Chair. Most recently he co-founded the ORS Musculoskeletal Infection (MSKI) Research Interest Group (RIG), Guest Edited JOR's Special Issue on MSKI, and Co-Chaired the ORS's 1st International Consensus Meeting (2023 ORS ICM on MSKI).

Previously known as the AO Research Fund Prize, the award was renamed the Berton Rahn Research Award in 2009 to recognize the numerous contributions made to the AO Foundation by former AO vice director Berton Rahn, whose histological work on bone remodeling is world-renowned.

Berton Rahn Research Award



Prof Dr med Dr med dent Berton Albert Anton Rahn
(1939-2008)

Background


The 'Berton Rahn Research Award' was established in recognition of Berton Rahn's immense contribution to the AO Foundation. The prize previously honored the best completed AO Start-up grant project of that year (based upon final reports and the publications resulting from all completed studies). Since 2017, the award is now open to any AO funded research. From August 2018, there is no longer an age limit for the award. The award consists of a keynote presentation at ARI's eCM conference (along with free registration, accommodation and travel to Davos) and a certificate.

Berton A Rahn

Here we inform you briefly about the Berton Rahn and his dedication to the Laboratory for Experimental Surgery Davos (LECD) and its continuation as AO Research Institute Davos (ARI), the AOCMF community and to the AO Foundation itself.



On March 26, 2008, Prof Dr med Dr med dent Berton Rahn passed away after a difficult illness. We as the AO Foundation family lost a friend, mentor and collaborator who dedicated himself to research for the Foundation in Davos. Berton was a highly respected scientist whose morphological-based bone histology is world-renowned and frequently used in AO



courses, though often unperceived by those who use and benefit from it. At the 2009 Trustees Meeting in Chicago, the former AO Research Fund Prize Award, which annually honors the best external start-up research fund project, was renamed the Berton Rahn Research Fund Prize Award in honor of his many contributions to the AO Foundation.

Berton grew up in Schaffhausen, Switzerland and first studied dentistry in Zürich until 1964 and medicine in Berlin until 1968. In 1968 he then joined the Laboratory for Experimental Surgery (now ARI) in Davos under the Directorship of Prof Stephan Perren. Berton stayed with AO for over 37 years. Berton received his doctorate in dentistry in 1970, followed by one in medicine in 1973. He qualified as an assistant professor and in 1985 became an associate professor at the University of Freiburg in Germany. In addition to his lecturing responsibilities at the university, he gave lectures on bone healing mainly based on his own research work, at the AO Courses in Davos and worldwide. He also contributed chapters on bone biology and fracture healing to several respected books. His animal studies in sheep on healing of mandibular fractures (1970–1972) were extremely important because they showed that the healing pattern in craniofacial bones (membraneous bones) is the same as in postcranial bones.

Berton was extremely interested in the microscopic pathology (histology) of bone healing and developed polychrome sequence labeling for newly formed bone (1969), used today worldwide in bone research. This technique also led to a decrease in the number of animals needed for research models. Berton also had strong interest in all forms of microscopy and interactions of cells within tissues and with cells and tissues to implants. Berton made important contributions to the development of craniomaxillofacial surgery as well as to the important field of dental implantology. The correction of deformed and damaged maxillofacial structures using Ilizarov's distraction method took some fundamental steps forward thanks to the clinical application of Berton Rahn's research. Berton was an active member of many societies and helped place AO Research on the world map. He was one of the original council members of the European Society for Biomaterials (ESB), helped organize their meeting in Davos in 1984 and 1993 and was chosen

as an honorary member in 2003. Berton was an author of more than 150 papers and has had several dozens of students pass through his hands, many of them earning their doctoral degree with his help. He always listened to his student's problems and liked to help them to solve these issues through their own reasoning. His research was characterized by its creativity, and above all by the support he offered to young researchers (including Geoff Richards in the early 90's).

Berton was vice-director of the ARI (from 1975 onwards) and was intimately involved in the design and building of the AO Center on Clavadelerstrasse in Davos which opened in 1992.




Berton was a reserved, sensitive man, but one who in the right moment could surprise with his unique dry sense of humor. His profound humanity made being in his company a great pleasure. In his short duration of retirement, he served as a Scientific Advisor to ARI until the symptoms of his illness manifested themselves in his bones, the very part of the body that he had spent a lifetime studying.

Berton's influence throughout the formative years of the AO Research Institute Davos, and the AO Foundation as a whole, is remembered with deep gratitude.

Prof R Geoff Richards, Director AO Research & Development

Prof Dr med Stephan M Perren, Honorary & Founding Member AO Foundation, past Director LECD & ARI

Prof Dr med Joachim Prein, Honorary Trustee, AO Foundation



Berton Rahn Research Award

Winner 2024:

Biographical Sketch

Edward M. Schwarz, Ph.D.




Dr. Edward Schwarz is the Burton Professor of Orthopaedics and Director of the Center for Musculoskeletal Research at the University of Rochester Medical Center, in Rochester, NY. He is a renowned Osteoimmunologist who has published more than 380 journal articles. He was funded by the Arthritis Foundation and National Multiple Sclerosis Society during his postdoctoral fellowship, has been continuously funded by the NIH since 1999, and served as Principal Investigator on R01, R21, R43, P01, P30 and P50 grants. He also served as Co-PI on the AO Trauma Clinical Priority Program – Bone Infection from 2012-2022. He served as Associate Editor of Arthritis Research & Therapy, Arthritis & Rheumatism, Journal of Bone & Joint Infection, and the Journal of Orthopaedic Research, and was just named Editor-in-Chief of JOR. His laboratory focuses on inflammatory bone loss, such as that seen in rheumatoid arthritis, infections, tumor metastasis and wear debris-induced osteolysis around loose prosthetic

implants. Dr. Schwarz is also a leader in orthopaedic biologic therapy, for which his lab has developed a novel passive immunization for MRSA and bone targeted antibiotics. Dr. Schwarz's lab is also interested in developing translational in vivo imaging outcome measures include near infrared imaging of lymphatic flow to detect arthritic flare, cone beam CT to assess bone healing in patients with orthopaedic implants, and intravital microscopy of bone infections. Dr. Schwarz has been an ORS member since 1999. He received the ORS's Harris Award in 2003, the ORS/AAOS Kappa Delta Award in 2005, and the CORR/ORS Richard Brand Award for outstanding Orthopaedic Research in 2015. He served on the ORS Board of Directors from 2006-2008, 2010-2011 and 2017-2019. He served the Orthopaedic Research and Education Foundation Study Section as a reviewer and Co-Chair from 2001-2007. He also served on many NIH Study Sections including Regular Membership and Co-Chair on Arthritis, Connective Tissue and Skin (ACTS, 2012-2016) and Musculoskeletal Tissue Engineering (MTE, 2017-2023). He has also served on the ORS Publications Committee as a member and Chair. Most recently he co-founded the ORS Musculoskeletal Infection (MSKI) Research Interest Group (RIG), Guest Edited JOR's Special Issue on MSKI, and Co-Chaired the ORS's 1st International Consensus Meeting (2023 ORS ICM on MSKI).


AO Funded Research

1. Discovery of *S. aureus* invasion and colonization of the osteocyte lacuno-canalicular network (OLCN) of cortical bone during chronic osteomyelitis. Figure: TEM evidence of submicron-elongated *S. aureus* in the osteocytic lacunar-canalicular network of infected live bone tissue. Long bones from mice (n = 5) infected with a UAMS-1 contaminated tibial pin (A-F, H, I), or a USA300 infected femoral osteotomy (G), were harvested on day 14 post-infection for TEM. (A) Low magnification TEM image of UAMS-1 invasion of live bone tissue (note osteocyte OC) in a canalculus (green arrow) communicating with the marrow cavity (MC). Also note the proximal neutrophils (yellow arrow) within the marrow. (B) Low magnification TEM image of UAMS-1 invasion of an osteocytic lacunar-canalicular adjacent to a channel infected with *S. aureus* (arrows) containing necrotic cells (*). Higher magnification TEM images (C, D) of UAMS-1 colonization of osteocytic lacunae. (E) Low magnification TEM image of three parallel canalculi in various states of colonization (1-severely infected, 2-moderately infected, and 3-uninfected) by the invading UAMS-1 within the live cortical bone. (F) Higher magnification TEM image measuring submicron-elongated

UAMS-1. (G) Similar bacterial invasion of canaliculi adjacent to the osteotomy (red arrow), and neutrophils in the marrow cavity (*) were observed in USA300 infected femurs, but not in long bones that received sterile implants (data not shown). (H) Low magnification TEM image documenting cortical bone damage adjacent to the infected tibia pin (red arrows), and a cavity filled with UAMS-1 (yellow bracket) that leads to a canaliculus (black arrow). (I) High magnification TEM of the infected cavity in H demonstrating mitotic *S. aureus* in the live cortical bone. Note that only the bacterium entering the canaliculus has an asymmetric septal plane (red arrows), which is aligned perpendicularly with the canaliculus orifice, perhaps to anchor and propel the emerging daughter cell into the submicron channel in the cortical bone during binary fission. (see de Mesy Bentley et al. *J Bone Miner Res.* 2017 May;32(5):985-90)



- Passive immunization with anti-glucosaminidase antibodies protect mice from MRSA osteomyelitis. Figure: Anti-Gmd mAb significantly increases internalization of *S. aureus* and megaclusters. Ultrathin section TEM was performed on RAW cells after 4hr of culture with MRSA opsonized with 1C11 (A) or αT2m (B). Note the megaclusters (arrowheads in A) are connected by a thick matrix (boxed region in A), whereas intracellular *S. aureus* in the control cultures were mostly individual bacterium (boxed region in B). Quantification confirmed that 1C11 significantly induced the % of internalized MRSA vs. αT2m (88.5 +/- 7.4 vs. 58.7 +/- 3.3; $p < 0.006$; $N = 4$ randomly chosen fields and the results are representative of duplicate experiments; Nu=nucleus; Cy=cytoplasm). Representative SEM of a macrophage phagocytosing a bacterium (arrow in C), and megaclusters inside of a macrophage (D), on the pins harvested on day 14 from 1C11 treated mice challenged with MRSA, which were not observed on pins harvested from PBS and ΔGmd treated mice. (see Varrone et al. *J Orthop Res.* 2014 Oct;32(10):1389-96)




- Anti-IsdB antibodies mediate Trojan horse leukocyte formation, *S. aureus* dissemination, and septic death. Figure: The role of *S. aureus* intracellular infection as a virulence mechanism in chronic osteomyelitis. Extensive TEM analyses of *S. aureus*-infected human bone samples failed to identify significant evidence of viable bone cells (osteoblasts, osteoclasts, osteocytes) containing intracellular bacteria, while all *S. aureus* colonized OLCN contain necrotic osteocytes (OC) with extracellular bacteria (red arrows) within osteocyte lacunae (a, TEM). In contrast, an acridine orange-stained smears of blood, harvested post-mortem from a patient that died from septic multiorgan failure, demonstrates

both extracellular bacteria (orange) and colonized leukocytes (yellow cells) via fluorescent

microscopy (b). c A higher power fluorescent image of the blood smear reveals a “Trojan horse” macrophage with cytoplasmic *S. aureus*, and acentric nucleus (fluorescent green). dTEM of this Trojan horse macrophage was performed via a “pop-off” technique, which

confirmed intracellular *S. aureus* cocci within the cytoplasm, adjacent to the nucleus (yellow arrow). (see Masters et al. Bone Res. 2019;7:20)



Publications for AO-funded research

Publications

- Gedbjerg N, Larosa R, Hunter JG, Varrone JJ, Kates SL, Schwarz EM, et al. Anti-Glucosaminidase IgG in Sera as a Biomarker of Host Immunity Against *Staphylococcus aureus* in Orthopaedic Surgery Patients. *J Bone Joint Surg Am*. 2013 Nov 20;95(22):e17111-9.
- Reizner W, Hunter JG, O'Malley NT, Southgate RD, Schwarz EM, Kates SL. A systematic review of animal models for *Staphylococcus aureus* osteomyelitis. *Eur Cell Mater*. 2014 Mar 25;27:196-212. Epub 2014/03/29.
- Schwarz EM, Kates SL, Alt V. The 1st International Consensus Meeting on Periprosthetic Joint Infection. *J Orthop Res*. 2014 Jan;32 Suppl 1:S1. Epub 2014/01/28.
- Varrone JJ, de Mesy Bentley KL, Bello-Irizarry SN, Nishitani K, Mack S, Hunter JG, et al. Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of *Staphylococcus aureus* megaclusters. *J Orthop Res*. 2014 Oct;32(10):1389-96.
- Farnsworth CW, Shehatou CT, Maynard R, Nishitani K, Kates SL, Zuscik MJ, et al. A humoral immune defect distinguishes the response to *Staphylococcus aureus* infections in mice with obesity and type 2 diabetes from that in mice with type 1 diabetes. *Infect Immun*. 2015 Jun;83(6):2264-74. Epub 2015/03/25.

6. Inzana JA, Schwarz EM, Kates SL, Awad HA. A novel murine model of established Staphylococcal bone infection in the presence of a fracture fixation plate to study therapies utilizing antibiotic-laden spacers after revision surgery. *Bone*. 2015 Mar;72:128-36.
7. Inzana JA, Trombetta RP, Schwarz EM, Kates SL, Awad HA. 3D printed bioceramics for dual antibiotic delivery to treat implant-associated bone infection. *Eur Cell Mater*. 2015 Nov 04;30:232-47.
8. Nishitani K, Beck CA, Rosenberg AF, Kates SL, Schwarz EM, Daiss JL. A Diagnostic Serum Antibody Test for Patients With Staphylococcus aureus Osteomyelitis. *Clin Orthop Relat Res*. 2015 Sep;473(9):2735-49.
9. Nishitani K, Sutipornpalangkul W, de Mesy Bentley KL, Varrone JJ, Bello-Irizarry SN, Ito H, et al. Quantifying the natural history of biofilm formation in vivo during the establishment of chronic implant-associated Staphylococcus aureus osteomyelitis in mice to identify critical pathogen and host factors. *J Orthop Res*. 2015 Sep;33(9):1311-9.
10. Inzana JA, Schwarz EM, Kates SL, Awad HA. Biomaterials approaches to treating implant-associated osteomyelitis. *Biomaterials*. 2016 Mar;81:58-71.
11. Moriarty TF, Kuehl R, Coenye T, Metsemakers WJ, Morgenstern M, Schwarz EM, et al. Orthopaedic device-related infection: current and future interventions for improved prevention and treatment. *EFORT Open Rev*. 2016 Apr;1(4):89-99. Epub 2017/05/04.
12. Nishitani K, Bello-Irizarry SN, de Mesy Bentley K, Daiss JL, Schwarz EM. The Role of the Immune System and Bone Cells in Acute and Chronic Osteomyelitis. *Osteoimmunology*. 2016;2nd Ed(Chapter 16):283-95.
13. de Mesy Bentley KL, Trombetta R, Nishitani K, Bello-Irizarry SN, Ninomiya M, Zhang L, et al. Evidence of Staphylococcus Aureus Deformation, Proliferation, and Migration in Canaliculi of Live Cortical Bone in Murine Models of Osteomyelitis. *J Bone Miner Res*. 2017 May;32(5):985-90. Epub 2016/12/10.
14. Farnsworth CW, Schott EM, Jensen SE, Zukoski J, Benvie AM, Refaai MA, et al. Adaptive Upregulation of Clumping Factor A (ClfA) by Staphylococcus aureus in the Obese, Type 2 Diabetic Host Mediates Increased Virulence. *Infect Immun*. 2017 Jun;85(6). Epub 2017/03/23.
15. Ishikawa M, de Mesy Bentley KL, McEntire BJ, Bal BS, Schwarz EM, Xie C. Surface topography of silicon nitride affects antimicrobial and osseointegrative properties of tibial implants in a murine model. *J Biomed Mater Res A*. 2017 Dec;105(12):3413-21. Epub 2017/09/03.
16. Moriarty TF, Schmid T, Post V, Samara E, Kates S, Schwarz EM, et al. A large animal model for a failed two-stage revision of intramedullary nail-related infection by methicillin-resistant Staphylococcus aureus. *Eur Cell Mater*. 2017 Aug 30;34:83-98. Epub 2017/08/31.
17. de Mesy Bentley KL, MacDonald A, Schwarz EM, Oh I. Chronic Osteomyelitis with Staphylococcus aureus Deformation in Submicron Canaliculi of Osteocytes: A Case Report. *JBJS Case Connect*. 2018 Jan-Mar;8(1):e8. Epub 2018/02/15.
18. Farnsworth CW, Schott EM, Benvie AM, Zukoski J, Kates SL, Schwarz EM, et al. Obesity/type 2 diabetes increases inflammation, periosteal reactive bone formation, and osteolysis during Staphylococcus aureus implant-associated bone infection. *J Orthop Res*. 2018 Jun;36(6):1614-23. Epub 2017/12/12.
19. Oh I, Muthukrishnan G, Ninomiya MJ, Brodell JD, Jr., Smith BL, Lee CC, et al. Tracking Anti-Staphylococcus aureus Antibodies Produced In Vivo and Ex Vivo during Foot Salvage Therapy for Diabetic Foot Infections Reveals Prognostic Insights and Evidence of Diversified Humoral Immunity. *Infect Immun*. 2018 Dec;86(12). Epub 2018/10/03.

20. Ricciardi BF, Muthukrishnan G, Masters E, Ninomiya M, Lee CC, Schwarz EM. Staphylococcus aureus Evasion of Host Immunity in the Setting of Prosthetic Joint Infection: Biofilm and Beyond. *Curr Rev Musculoskelet Med*. 2018 Sep;11(3):389-400. Epub 2018/07/11.
21. Trombetta RP, Dunman PM, Schwarz EM, Kates SL, Awad HA. A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants. *mSphere*. 2018 Oct 31;3(5). Epub 2018/11/02.
22. Yokogawa N, Ishikawa M, Nishitani K, Beck CA, Tsuchiya H, Mesfin A, et al. Immunotherapy synergizes with debridement and antibiotic therapy in a murine 1-stage exchange model of MRSA implant-associated osteomyelitis. *J Orthop Res*. 2018 Jun;36(6):1590-8. Epub 2018/02/07.
23. Masters EA, Salminen AT, Begolo S, Luke EN, Barrett SC, Overby CT, et al. An in vitro platform for elucidating the molecular genetics of S. aureus invasion of the osteocyte lacuno-canalicular network during chronic osteomyelitis. *Nanomedicine*. 2019 Oct;21:102039. Epub 2019/06/28.
24. Masters EA, Trombetta RP, de Mesy Bentley KL, Boyce BF, Gill AL, Gill SR, et al. Evolving concepts in bone infection: redefining "biofilm", "acute vs. chronic osteomyelitis", "the immune proteome" and "local antibiotic therapy". *Bone Res*. 2019;7:20. Epub 2019/10/28.
25. Muthukrishnan G, Masters EA, Daiss JL, Schwarz EM. Mechanisms of Immune Evasion and Bone Tissue Colonization That Make Staphylococcus aureus the Primary Pathogen in Osteomyelitis. *Curr Osteoporos Rep*. 2019 Dec;17(6):395-404. Epub 2019/11/14.
26. Saeed K, McLaren AC, Schwarz EM, Antoci V, Arnold WV, Chen AF, et al. 2018 international consensus meeting on musculoskeletal infection: Summary from the biofilm workgroup and consensus on biofilm related musculoskeletal infections. *J Orthop Res*. 2019 May;37(5):1007-17. Epub 2019/01/23.
27. Schwarz EM, Parvizi J, Gehrke T, Aiyer A, Battenberg A, Brown SA, et al. 2018 International Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly Questions. *J Orthop Res*. 2019 May;37(5):997-1006. Epub 2019/04/13.
28. Trombetta RP, de Mesy Bentley KL, Schwarz EM, Kate SL, Awad HA. A murine femoral ostectomy model with hardware exchange to assess antibiotic-impregnated spacers for implant-associated osteomyelitis. *Eur Cell Mater*. 2019 Jun 27;37:431-43. Epub 2019/06/28.
29. Trombetta RP, Ninomiya MJ, El-Atawneh IM, Knapp EK, de Mesy Bentley KL, Dunman PM, et al. Calcium Phosphate Spacers for the Local Delivery of Sifloxacin and Rifampin to Treat Orthopedic Infections: Efficacy and Proof of Concept in a Mouse Model of Single-Stage Revision of Device-Associated Osteomyelitis. *Pharmaceutics*. 2019 Feb 22;11(2). Epub 2019/03/01.
30. Hao SP, Masters EA, Ninomiya MJ, Beck CA, Schwarz EM, Daiss JL, et al. Species-Specific Immunoassay Aids Identification of Pathogen and Tracks Infectivity in Foot Infection. *Foot Ankle Int*. 2020 Nov 9:1071100720965136. Epub 2020/11/10.
31. Kates SL, Owen JR, Beck CA, Xie C, Muthukrishnan G, Daiss JL, et al. Lack of Humoral Immunity Against Glucosaminidase Is Associated with Postoperative Complications in Staphylococcus aureus Osteomyelitis. *J Bone Joint Surg Am*. 2020 Nov 4;102(21):1842-8. Epub 2020/08/29.
32. Lee CC, Southgate RD, Jiao C, Gersz E, Owen JR, Kates SL, et al. Deriving a dose and regimen for anti-glucosaminidase antibody passive-immunisation for patients with Staphylococcus aureus osteomyelitis. *Eur Cell Mater*. 2020 Jan 31;39:96-107. Epub 2020/02/01.
33. Masters EA, de Mesy Bentley KL, Gill AL, Hao SP, Galloway CA, Salminen AT, et al. Identification of Penicillin Binding Protein 4 (PBP4) as a critical factor for Staphylococcus aureus bone invasion during osteomyelitis in mice. *PLoS Pathog*. 2020 Oct 22;16(10):e1008988. Epub 2020/10/23.

34. Muthukrishnan G, Sooin S, Beck CA, Grier A, Brodell JD, Jr., Lee CC, et al. A Bioinformatic Approach to Utilize a Patient's Antibody-Secreting Cells against Staphylococcus aureus to Detect Challenging Musculoskeletal Infections. *Immunohorizons*. 2020 Jun 22;4(6):339-51. Epub 2020/06/24.
35. Nishitani K, Ishikawa M, Morita Y, Yokogawa N, Xie C, de Mesy Bentley KL, et al. IsdB antibody-mediated sepsis following S. aureus surgical site infection. *JCI Insight*. 2020 Oct 2;5(19). Epub 2020/10/03.
36. Ricciardi BF, Muthukrishnan G, Masters EA, Kaplan N, Daiss JL, Schwarz EM. New developments and future challenges in prevention, diagnosis, and treatment of prosthetic joint infection. *J Orthop Res*. 2020 Jan 22. Epub 2020/01/23.
37. Sulovari A, Ninomiya MJ, Beck CA, Ricciardi BF, Ketonis C, Mesfin A, et al. Clinical utilization of species-specific immunoassays for identification of Staphylococcus aureus and Streptococcus agalactiae in orthopedic infections. *J Orthop Res*. 2020 Dec 4. Epub 2020/12/05.
38. de Mesy Bentley KL, Galloway CA, Muthukrishnan G, Echemnach SR, Masters EA, Zeiter S, et al. Emerging electron microscopy and 3D methodologies to interrogate Staphylococcus aureus osteomyelitis in murine models. *J Orthop Res*. 2021 Feb;39(2):376-88. Epub 2020/12/31.
39. Masters EA, Hao SP, Kenney HM, Morita Y, Galloway CA, de Mesy Bentley KL, et al. Distinct vasculotropic versus osteotropic features of S. agalactiae versus S. aureus implant-associated bone infection in mice. *J Orthop Res*. 2021 Feb;39(2):389-401. Epub 2020/12/19.
40. Masters EA, Muthukrishnan G, Ho L, Gill AL, de Mesy Bentley KL, Galloway CA, et al. Staphylococcus aureus Cell Wall Biosynthesis Modulates Bone Invasion and Osteomyelitis Pathogenesis. *Front Microbiol*. 2021;12:723498. Epub 2021/09/07.
41. Metsemakers WJ, Zalavras C, Schwarz EM, Chen AF, Trampuz A, Moriarty TF. Antimicrobial Resistance, the COVID-19 Pandemic, and Lessons for the Orthopaedic Community. *J Bone Joint Surg Am*. 2021 Jan 6;103(1):4-9. Epub 2020/12/02.
42. Moriarty TF, Muthukrishnan G, Daiss JL, Xie C, Nishitani K, Morita Y, et al. Bone infection: a clinical priority for clinicians, scientists and educators. *Eur Cell Mater*. 2021 Oct 18;42:312-33. Epub 2021/10/19.
43. Morita Y, Masters EA, Schwarz EM, Muthukrishnan G. Interleukin-27 and Its Diverse Effects on Bacterial Infections. *Front Immunol*. 2021;12:678515. Epub 2021/06/04.
44. Muthukrishnan G, Wallimann A, Rangel-Moreno J, Bentley KLM, Hildebrand M, Mys K, et al. Humanized Mice Exhibit Exacerbated Abscess Formation and Osteolysis During the Establishment of Implant-Associated Staphylococcus aureus Osteomyelitis. *Front Immunol*. 2021;12:651515. Epub 2021/04/06.
45. Owen JR, Campbell MP, Mott MD, Beck CA, Xie C, Muthukrishnan G, et al. IgG4-specific responses in patients with Staphylococcus aureus bone infections are not predictive of postoperative complications. *Eur Cell Mater*. 2021 Sep 22;42:156-65. Epub 2021/09/23.
46. Saeed K, Sendi P, Arnold WV, Bauer TW, Coraca-Huber DC, Chen AF, et al. Bacterial toxins in musculoskeletal infections. *J Orthop Res*. 2021 Feb;39(2):240-50. Epub 2020/04/08.
47. Schwarz EM, Arts JJC, Chen AF. Introduction for the Journal of Orthopaedic Research Special Issue on musculoskeletal infection. *J Orthop Res*. 2021 Feb;39(2):225-6. Epub 2021/01/19.
48. Schwarz EM, McLaren AC, Sculco TP, Brause B, Bostrom M, Kates SL, et al. Adjuvant antibiotic-loaded bone cement: Concerns with current use and research to make it work. *J Orthop Res*. 2021 Feb;39(2):227-39. Epub 2020/01/31.

49. Masters EA, Ricciardi BF, Bentley KLM, Moriarty TF, Schwarz EM, Muthukrishnan G. Skeletal infections: microbial pathogenesis, immunity and clinical management. *Nat Rev Microbiol.* 2022 Jul;20(7):385-400. Epub 2022/02/17.
50. Moriarty TF, Metsemakers WJ, Morgenstern M, Hofstee MI, Vallejo Diaz A, Cassat JE, et al. Fracture-related infection. *Nat Rev Dis Primers.* 2022 Oct 20;8(1):67. Epub 2022/10/21.
51. Morita Y, Saito M, Rangel-Moreno J, Franchini AM, Owen JR, Martinez JC, et al. Systemic IL-27 administration prevents abscess formation and osteolysis via local neutrophil recruitment and activation. *Bone Res.* 2022 Aug 26;10(1):56. Epub 2022/08/27.
52. Schwarz EM. What Are the Immune Responses That Allow Us to Live With Incurable Bone Infection, and How Can They Be Augmented to Improve Outcomes After Prosthetic Joint Infection? *J Bone Miner Res.* 2022 May;37(5):824-5. Epub 2022/04/19.
53. Sherchand SP, Adhikari RP, Muthukrishnan G, Kanipakala T, Owen JR, Xie C, et al. Evidence of Neutralizing and Non-Neutralizing Anti-Glucosaminidase Antibodies in Patients With *S. Aureus* Osteomyelitis and Their Association With Clinical Outcome Following Surgery in a Clinical Pilot. *Front Cell Infect Microbiol.* 2022;12:876898. Epub 2022/08/05.
54. Hickok NJ, Li B, Oral E, Zaat SAJ, Armbruster DA, Atkins GJ, et al. The 2023 Orthopaedic Research Society's International Consensus Meeting on Musculoskeletal Infection: Summary from the In Vitro Section. *J Orthop Res.* 2023 Dec 25. Epub 2023/12/26.
55. Jennings JA, Arts JJ, Abuhussein E, Alt V, Ashton N, Baertl S, et al. 2023 International Consensus Meeting on musculoskeletal infection: Summary from the treatment workgroup and consensus on treatment in preclinical models. *J Orthop Res.* 2023 Dec 9. Epub 2023/12/10.
56. Moriarty TF, Hickok NJ, Saeed K, Schaer TP, Chen AF, Schwarz EM. The 2023 Orthopaedic Research Society International Consensus Meeting on musculoskeletal infection. *J Orthop Res.* 2023 Oct 12. Epub 2023/10/12.
57. Schwarz EM, Archer NK, Atkins GJ, Bentley KLM, Botros M, Cassat JE, et al. The 2023 Orthopaedic Research Society's International Consensus Meeting on musculoskeletal infection: Summary from the host immunity section. *J Orthop Res.* 2023 Dec 16. Epub 2023/12/16.
58. Xie C, Ren Y, Weeks J, Rainbolt J, Kenney HM, Xue T, et al. Longitudinal intravital imaging of the bone marrow for analysis of the race for the surface in a murine osteomyelitis model. *J Orthop Res.* 2023 Oct 9. Epub 2023/10/09.

Leveraged extramural research grants that resulted from AO research funding.

Public Health Service, NIAMS, R21 AR081050 Quantifying the Race for the Surface Principal Investigator, Edward M. Schwarz, Ph.D.	\$577,500	7/1/22-6/30/24
Public Health Service, NIAID, Phase 2 SBIR R44AI155309 Immunotherapy of MRSA Osteomyelitis Paid Consultant, Edward M. Schwarz, Ph.D. (Integrated Biotherapeutics, Inc.)	\$2,791,540	7/1/22-6/30/25
Public Health Service, NIAID, Phase 1&2 SBIR R44 AI175069 Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures Paid Consultant, Edward M. Schwarz, Ph.D. (Biovinc Inc.)	\$ 2,134,423	12/1/22-11/30/25 A
Public Health Service, NIAMS, P50 AR72000 Translating the Osteoimmunology of Bone Infection Contact PI, PI of the Administration Core and Project 2, Edward M. Schwarz, Ph.D.	\$17,000,000	10/01/17 - 9/30/27

Previous Berton Rahn Research Award Winners

2023



Ria Versus BMC as orthobiologic augments to allografts

Brett Crist Vice Chair of Business Development, Director of the Orthopaedic Trauma Service, Director of the Orthopaedic Trauma Fellowship, Director of the Limb Preservation Center, and is a tenured Professor of the Department of Orthopaedic Surgery at the University of Missouri Health, USA

2022



CRP Annulus Fibrosus Rupture (AFR) (ANNUMECH)

Establish the functional requirements for next-generation annulus repair methods through iterative, parametric experimental and simulation studies, to develop methods for the fabrication of novel biomaterial-based repair devices, and to validate their mechanical and biological performance in organ models

Stephen Ferguson, Institute for Biomechanics, ETH Zurich, Switzerland

2021



3D printed constructs for osteochondral defect repair

Jos Malda, Department of Orthopaedics, University Medical Center Utrecht and the Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Utrecht, The Netherlands

2020



Rapid Prototyping of Custom-Made Bone-Forming Tissue Engineering Constructs & Projects on 3D printing in collaboration with ARI consortia

Ling Qin, Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, China

2019



Projects on Fracture Related Infection in collaboration with AOTrauma Clinical Priority Program Bone Infection, ARI and AOTK

Willem-Jan Metsemakers, UZ Leuven, Department of Trauma Surgery, Leuven, The Netherlands

2018



CRP Annulus Fibrosus Rupture (AFR): (ANNUPHEN)

Characterization of intervertebral disc cells and identification on a suitable cell source for efficient tissue regeneration

Daisuke Sakai, Tokai University School of Medicine in Kanagawa, Japan

2017



CRP Acute Cartilage Injury (ACI): (HiCartia)

A novel platform for optimizing material design for cartilage tissue engineering and enabling drug discovery for cartilage restoration

Robert Mauck, University of Pennsylvania (USA)

2016



Project S-12-27S:

Targeting endothelial to mesenchymal transition in fibrodysplasia ossificans progressive

Gonzalo Sánchez Duffhues, Leiden University Medical Center (NL)

2015



Project S-10-07L:

Controlling nanotopography-ECM environment for enhanced bone formation with hMSCs

Jung Yul Lim, University of Nebraska-Lincoln (USA)

2014



Project S-10-62Y:

Stem cell mobilization for enhanced bone healing

Clare Yellowley, University of California Davis (USA)

2013



Project S-07-1C:

Can low intensity pulsed ultrasound accelerate osteoporotic fracture healing?

Wing-Hoi Cheung, The Chinese University of Hong Kong (China)

2012



Project S-05-95J:

In-situ crosslinkable osteoinductive poly(lactide) scaffold for bone regeneration

Esmail Jabbari, University of South Carolina (USA)

2011



Project F-07-43L:

A pilot study of interleukin-12 local delivery for infection prevention after a traumatic open fracture

Bingyun Li, West Virginia University (USA)

2010



Project 04-J44:

Skeletal effects of estrogen

Teppo Järvinen, University of Tampere (Finland)


2009 (2 winners)



Project 04-I58:

Effects of cyclic compression on intervertebral disc cell metabolism

James C Iatridis, University of Vermont (USA)



Project 04-K3:

Unravelling endogenous mechanisms of bone regeneration through quantification of the interplay between bone cells and their environment

Melissa Knothe Tate, Cleveland Clinic Foundation (USA)